Newest Update on Deanna Protocol

A recent article was released in March 2017, that examined an earlier study on the Deanna Protocol (DP). The newest study concluded:

Targeting energy metabolism with the DP supplement as a metabolic therapy produces a change in the global metabolic profile of ALS mice that support the role of the DP for enhanced mitochondrial energy metabolism and prolongs time to paralysis of ALS C. elegans. (1)

For more information on the original article on please view the original article at: https://link.springer.com/article/10.1007/s11306-017-1183-1

If you need information on how the Deanna Protocol can help you please contact us today for details and assistance.

References

Ari, C., Poff, A.M., Held, H.E., Landon, C.S., Goldhagen, C.R., Mavromates, N., et al. (2014). Metabolic therapy with Deanna protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model. PLoS One, 9(7), e103526. doi:10.1371/journal.pone.0103526.CrossRefPubMedPubMedCentralGoogle Scholar
Ash, P.E., Zhang, Y.J., Roberts, C.M., Saldi, T., Hutter, H., Buratti, E., et al. (2010). Neurotoxic effects of TDP-43 overexpression in C. elegans. Human Molecular Genetics, 19(16), 3206–3218. doi:10.1093/hmg/ddq230.CrossRefPubMedPubMedCentralGoogle Scholar
Bodhicharla, R., Nagarajan, A., Winter, J., Adenle, A., Nazir, A., Brady, D., et al. (2012). Effects of alpha-synuclein overexpression in transgenic Caenorhabditis elegans strains. CNS Neurological Disorders Drug Targets, 11(8), 965–975.CrossRefPubMedPubMedCentralGoogle Scholar
Boros, L.G., D’Agostino, D.P., Katz, H.E., Roth, J.P., Meuillet, E.J., Somlyai, G. (2016) Submolecular regulation of cell transformation by deuterium depleting water exchange reactions in the tricarboxylic acid substrate cycle. Medical hypotheses, 87, 69–74. doi:10.1016/j.mehy.2015.11.016.CrossRefPubMedGoogle Scholar
Brignull, H.R., Morley, J.F., Garcia, S.M., & Morimoto, R.I. (2006). Modeling polyglutamine pathogenesis in C. elegans. Methods in Enzymology, 412, 256–282. doi:10.1016/S0076-6879(06)12016-9.CrossRefPubMedGoogle Scholar
De Feyter, H.M., Behar, K.L., Rao, J.U., Madden-Hennessey, K., Ip, K.L., Hyder, F., Drewes, L.R., Geschwind, J.F., de Graaf, R.A., & Rothman, D.L. (2016). A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth. Neuro-Oncology, 18(8), 1079–1087. doi:10.1093/neuonc/now088.CrossRefPubMedGoogle Scholar
Dupuis, L., Pradat, P.-F.F., Ludolph, A.C., & Loeffler, J.-P.P. (2010). Energy metabolism in amyotrophic lateral sclerosis. The Lancet Neurology, 10(1), 75–82. doi:10.1016/s1474-4422(10)70224-6.CrossRefGoogle Scholar
Edwards, C., Canfield, J., Copes, N., Brito, A., Rehan, M., Lipps, D., et al. (2015). Mechanisms of amino acid-mediated lifespan extension in Caenorhabditis elegans. BMC genetics, 16, 8. doi:10.1186/s12863-015-0167-2.CrossRefGoogle Scholar
Edwards, C., Canfield, J., Copes, N., Rehan, M., Lipps, D., & Bradshaw, P.C. (2014). D-beta-hydroxybutyrate extends lifespan in C. elegans. Aging (Albany NY), 6(8), 621–644.CrossRefPubMedPubMedCentralGoogle Scholar
Edwards, C.B., Copes, N., Brito, A.G., Canfield, J., & Bradshaw, P.C. (2013). Malate and fumarate extend lifespan in Caenorhabditis elegans. PLoS One, 8(3), e58345. doi:10.1371/journal.pone.0058345.CrossRefGoogle Scholar
Group, A. L., Fournier, C., Bedlack, B., Hardiman, O., Heiman-Patterson, T., Gutmann, L., et al (2013). ALS untangled no. 20: The Deanna protocol. Amyotrophic lateral sclerosis & frontotemporal degeneration, 14(4), 319–323. doi:10.3109/21678421.2013.788405.CrossRefGoogle Scholar
Gunther, M.R., Vangilder, R., Fang, J., & Beattie, D.S. (2004). Expression of a familial amyotrophic lateral sclerosis-associated mutant human superoxide dismutase in yeast leads to decreased mitochondrial electron transport. Archives of Biochemistry and Biophysics, 431(2), 207–214. doi:10.1016/j.abb.2004.08.009.CrossRefGoogle Scholar
Hartman, A.L., Gasior, M., Vining, E.P., & Rogawski, M.A. (2007). The neuropharmacology of the ketogenic diet. Pediatric neurology, 36(5), 281–292. doi:10.1016/j.pediatrneurol.2007.02.008.CrossRefGoogle Scholar
Henderson, S.T. (2008). Ketone bodies as a therapeutic for Alzheimer’s disease. Neurotherapeutics, 5(3), 470–480. doi:10.1016/j.nurt.2008.05.004.CrossRefGoogle Scholar
Jung, C., Higgins, C. M.J., & Xu, Z. (2002). Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis. Journal of Neurochemistry, 83(3), 535–545. doi:10.1046/j.1471-4159.2002.01112.x.CrossRefGoogle Scholar
McColl, G., Roberts, B.R., Pukala, T.L., Kenche, V.B., Roberts, C.M., Link, C.D., et al. (2012). Utility of an improved model of amyloid-beta (Abeta(1)(-)(4)(2)) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease. Molecular Neurodegeneration, 7, 57. doi:10.1186/1750-1326-7-57.CrossRefGoogle Scholar
Menzies, F.M., Cookson, M.R., Taylor, R.W., Turnbull, D.M., Chrzanowska-Lightowlers, Z.M.A., Dong, L., et al. (2002). Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain, 125(7), 1522–1533. doi:10.1093/brain/awf167.CrossRefGoogle Scholar
Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, T.T., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314(5796), 130–133. doi:10.1126/science.1134108.CrossRefGoogle Scholar
Papamandjaris, A.A., MacDougall, D.E., & Jones, P.J. (1997). Medium chain fatty acid metabolism and energy expenditure: Obesity treatment implications. Life sciences, 62(14), 1203–1215.CrossRefGoogle Scholar
Powell, C.S., & Jackson, R.M. (2003). Mitochondrial complex I, aconitase, and succinate dehydrogenase during hypoxia-reoxygenation: Modulation of enzyme activities by MnSOD. American journal of physiology. Lung cellular and molecular physiology, 285(1), 98. doi:10.1152/ajplung.00253.2002.CrossRefGoogle Scholar
Prins, M.L. (2007). Cerebral metabolic adaptation and ketone metabolism after brain injury. Journal of cerebral blood flow and metabolism, 28(1), 1–16. doi:10.1038/sj.jcbfm.9600543.CrossRefGoogle Scholar
Scotter, E.L., Chen, H.J., & Shaw, C.E. (2015). TDP-43 proteinopathy and ALS: Insights into disease mechanisms and therapeutic targets. Neurotherapeutics, 12(2), 352–363. doi:10.1007/s13311-015-0338-x.CrossRefGoogle Scholar
Sidossis, L.S., Stuart, C.A., Shulman, G.I., Lopaschuk, G.D., & Wolfe, R.R. (1996). Glucose plus insulin regulate fat oxidation by controlling the rate of fatty acid entry into the mitochondria. Journal of Clinical Investigation, 98(10), 2244–2250.CrossRefGoogle Scholar
Slocum, R.D. (2005). Genes, enzymes and regulation of arginine biosynthesis in plants. Plant Physiology and Biochemistry, 43(8), 729745, doi:10.1016/j.plaphy.2005.06.007.CrossRefGoogle Scholar
Stiernagle, T. (2006). Maintenance of C. elegans. In The C. elegans Research Community (Ed.), WormBook (pp. 1–11). doi:10.1895/wormbook.1.101.1.
Struys, E.A., Verhoeven, N.M., Jansen, E.W.E., ten Brink, H.J., Gupta, M., Burlingame, T.G., et al. (2006). Metabolism of γ-hydroxybutyrate to d-2-hydroxyglutarate in mammals: Further evidence for d-2-hydroxyglutarate transhydrogenase. Metabolism, 55(3), 353358. doi:10.1016/j.metabol.2005.09.009.CrossRefGoogle Scholar
Ting Wong, C.G., Bottiglieri, T., & Snead, O.C. (2003). GABA, γ-hydroxybutyric acid, and neurological disease. Annals of neurology, 54, S3–S12. doi:10.1002/ana.10696.CrossRefGoogle Scholar
VanItallie, T.B., & Nufert, T.H. (2003). Ketones: Metabolism’s ugly duckling. Nutrition Reviews, 61(10), 327–341.CrossRefGoogle Scholar
Veech, R.L., Chance, B., Kashiwaya, Y., Lardy, H.A., & Cahill, G.F. (2001). Ketone bodies, potential therapeutic uses. IUBMB Life, 51(4), 241–247. doi:10.1080/152165401753311780.CrossRefGoogle Scholar
Veldink, J.H., Kalmijn, S., Groeneveld, G., Wunderink, W., Koster, A., de Vries, J.H.M, et al. (2007). Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry, 78(4), 367–371. http://doi.org/10.1136/jnnp.2005.083378.
Wei, Z., Merina, V., Prashant, V., Anastasiya, D., Alice, C., Jun, W., et al. (2012). Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease. PLoS One. doi:10.1371/journal.pone.0049191.Google Scholar
Wiedemann, F.R., Manfredi, G., Mawrin, C., Beal, M.F., & Schon, E.A. (2002). Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. Journal of Neurochemistry, 80(4), 616–625. doi:10.1046/j.0022-3042.2001.00731.x.CrossRefGoogle Scholar
Winton, M.J., Igaz, L.M., Wong, M.M., Kwong, L.K., Trojanowski, J.Q., & Lee, V.M. (2008). Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. The Journal of biological chemistry, 283(19), 13302–13309. doi:10.1074/jbc.M800342200.CrossRefGoogle Scholar
Xu, Y., Labedan, B., & Glansdorff, N. (2007). Surprising arginine biosynthesis: A reappraisal of the enzymology and evolution of the pathway in microorganisms. Microbiology and Molecular Biology Reviews, 71(1), 36–47. doi:10.1128/MMBR.00032-06.CrossRefPubMedPubMedCentralGoogle Scholar
Zhao, Z., Lange, D.J., Voustianiouk, A., MacGrogan, D., Ho, L., Suh, J., Humala, N., Thiyagarajan, M., Wang, J., Pasinetti, G.M. (2006) A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neuroscience, 3(7), 29.CrossRefGoogle Scholar
Zhao, W., Varghese, M., Vempati, P., Dzhun, A., Cheng, A., Wang, J., Lange, D., Bilski, A., Faravelli, I., Pasinetti, G.M. (2012) Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease. PLoS One, 7(11):e49191. doi:10.1371/journal.pone.0049191.CrossRefGoogle Scholar